A safety paper reports results broadly comparable with placebo. A later regulatory summary flags possible serious adverse events. If both concern AOD-9604, which should a reader believe? The useful answer begins with what each source actually examined: particular clinical preparations and observation periods in one case, and unresolved safety questions about compounded preparations in the other.[8][1]
The reassuring evidence deserves attention. So do its boundaries. Reading those together is more informative than treating either “well tolerated” or “potential risk” as a verdict on every vial bearing the same name.
What the six trials actually tested
In 2013, Heike Stier, Evert Vos and David Kenley published a safety evaluation of six AOD-9604 trials conducted between 2001 and 2006, involving 893 participants across treatment and comparison groups.[8] The studies were double-blind and placebo-controlled; most participants were adults with obesity who were otherwise considered healthy, and the first four studies enrolled men only.[8]
AOD-9604 is a synthetic, 16-amino-acid molecule based on the carboxy-terminal region of human growth hormone, with an additional tyrosine residue.[8] It was investigated for effects on fat metabolism, but the paper's stated purpose was to evaluate safety and tolerability.[8] A favorable safety assessment therefore should not be read as proof of a meaningful weight-loss benefit.
Two trials examined intravenous administration. Four examined oral capsules or tablets, with the longest treatment period lasting 24 weeks.[8] The intravenous trials used single administrations separated by observation periods; the months-long evidence came from oral treatment.[8] Combining these into “six human trials” can conceal the distinction that matters most when someone tries to apply the results to repeated injections.
The reassuring findings are specific and useful
The researchers reported no significant treatment-related differences in circulating IGF-1, a growth-related signaling protein, and no deterioration in the measured glucose-tolerance outcomes relative to placebo.[8] These were deliberate safety questions because of the molecule's relationship to growth hormone.[8] Antibodies against AOD-9604 were not detected in the tested samples; the largest trial's antibody analysis covered a selected subset of participants.[8]
The overall adverse-event profiles were often similar between active treatment and placebo, including in the 24-week oral study.[8] That comparison matters: an event occurring during a trial is not automatically caused by the intervention. A placebo group helps researchers examine whether a pattern differs with treatment.
| Evidence in the paper | What it supports | What remains outside it |
|---|---|---|
| Two intravenous trials.[8] | ||
| Reassuring short-term findings in the studied men. | Repeated injections over months or another injection route. | |
| Oral studies extending to 24 weeks.[8] | ||
| Tolerability information for those preparations and participants. | Years of use or an unspecified research product. | |
| No antibodies detected in tested samples.[8] | ||
| No detected antibody response within that testing. | Absence of immune reactions with every formulation and route. | |
| No significant IGF-1 or glucose-tolerance deterioration.[8] | ||
| Reassurance on those measured outcomes. | Proof of weight-loss efficacy or comprehensive long-term safety. |
“Well tolerated” also does not mean “nothing happened.” In one oral study, the results describe a serious diarrhea event judged “possibly related” to treatment, despite the paper's broader statements that no treatment-related serious events occurred.[8] Another oral study reported more headaches, diarrhea and flatulence in its highest-exposure group.[8] These details qualify the favorable summary without erasing it.
Funding and follow-up belong in the interpretation
The authors acknowledged that Metabolic Pharmaceuticals funded all six trials.[8] Their declared interests included Kenley's 6.9% holding in Calzada, which owned Metabolic; Vos's consultancy and former medical-director role; and Stier's employment at a consultancy advising Metabolic on possible European food applications.[8] These are relevant interests to disclose, not proof that the results are invalid.
The same careful reading applies to time. A 24-week oral study can describe what was observed during that period; it cannot establish outcomes after years of exposure or in populations excluded from the trials.[8] Nor can reassuring averages guarantee that an uncommon event would have been detected. Those are limits of the evidence, not findings of hidden harm.
The paper also reports serious events, including cancer diagnoses, in the 12-week study; investigators judged those events unrelated to treatment.[8] Their occurrence does not establish that AOD-9604 caused cancer. Equally, that judgment and the measured IGF-1 results should not be expanded into a universal claim that long-term cancer risk has been ruled out.
What FDA's later concerns add
FDA's safety summary dated April 2026 identifies possible immune-response risks for certain routes, difficulties characterizing the active ingredient and related impurities, and insufficient safety information about AOD-9604.[1] It also states that serious adverse events may be associated with the compound, while explicitly saying causality is unclear.[1]
That wording describes uncertainty requiring attention. It does not say every exposure is toxic, identify a reliable event rate, or prove that the compound caused each reported event.[1] The summary does not identify which events underpin its AOD-9604 statement, so they should not simply be assumed to be the events described in the 2013 paper.[1][8]
In that dated FDA page, AOD-9604 appears under substances whose nominations were withdrawn, rather than the separate current category-2 table.[1] A reader should not turn that placement into either a drug-approval claim or a finding that the safety questions have disappeared.
Why the findings do not qualify a research vial for human use
The clinical paper describes a specified manufacturer, production under current good manufacturing practices, and defined intravenous and oral formulations.[8] A research material with the same name has not thereby been shown equivalent to those preparations. A label and a purity percentage alone cannot establish complete identity, sterility, clinical safety or comparable exposure by a particular route.[1][2][8]
Reconstitution does not fill those evidentiary gaps. FDA explains that injectable products bypass some defenses against toxins and microorganisms, creating a potential for serious harm.[2] Its June 2026 warning letter concerned other named products, but illustrates why “research use only” wording cannot resolve human-use concerns when a product is promoted for that purpose.[2]
Research materials should not be consumed or self-administered. The favorable AOD-9604 trials remain useful evidence about what their investigators studied. They do not supply the missing product-specific and route-specific evidence needed to treat an unverified research preparation as a medicine.[1][2][8]